Parkman Healthcare Partners LLC Has $1.96 Million Stock Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Parkman Healthcare Partners LLC grew its position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 465.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 578,511 shares of the company's stock after purchasing an additional 476,118 shares during the period. Parkman Healthcare Partners LLC owned 0.39% of Xeris Biopharma worth $1,961,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of XERS. Nuveen Asset Management LLC lifted its holdings in shares of Xeris Biopharma by 13.6% during the 4th quarter. Nuveen Asset Management LLC now owns 1,903,442 shares of the company's stock worth $6,453,000 after acquiring an additional 228,380 shares during the period. Occudo Quantitative Strategies LP raised its holdings in Xeris Biopharma by 57.8% in the fourth quarter. Occudo Quantitative Strategies LP now owns 51,737 shares of the company's stock valued at $175,000 after buying an additional 18,952 shares during the period. Millennium Management LLC raised its holdings in Xeris Biopharma by 34.8% in the fourth quarter. Millennium Management LLC now owns 1,948,552 shares of the company's stock valued at $6,606,000 after buying an additional 502,853 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Xeris Biopharma by 4.5% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 80,388 shares of the company's stock valued at $273,000 after buying an additional 3,447 shares during the period. Finally, Graham Capital Management L.P. raised its stake in shares of Xeris Biopharma by 32.2% during the fourth quarter. Graham Capital Management L.P. now owns 70,662 shares of the company's stock valued at $240,000 after purchasing an additional 17,209 shares during the period. 42.75% of the stock is owned by institutional investors and hedge funds.

Xeris Biopharma Stock Down 0.1%

XERS stock traded down $0.01 during mid-day trading on Monday, reaching $4.88. The company had a trading volume of 379,267 shares, compared to its average volume of 2,625,521. The stock has a market capitalization of $762.38 million, a P/E ratio of -10.83 and a beta of 1.10. Xeris Biopharma Holdings, Inc. has a one year low of $1.86 and a one year high of $6.07. The stock's 50-day simple moving average is $4.72 and its two-hundred day simple moving average is $3.91.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.01. The business had revenue of $57.80 million for the quarter, compared to analysts' expectations of $57.61 million. On average, research analysts forecast that Xeris Biopharma Holdings, Inc. will post -0.41 EPS for the current fiscal year.

Insider Transactions at Xeris Biopharma

In other Xeris Biopharma news, insider Beth Hecht sold 40,000 shares of the stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $5.43, for a total transaction of $217,200.00. Following the completion of the transaction, the insider now directly owns 1,353,510 shares in the company, valued at $7,349,559.30. This represents a 2.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 6.47% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on XERS. Piper Sandler reiterated a "neutral" rating and set a $4.00 price objective (up previously from $3.00) on shares of Xeris Biopharma in a research note on Friday, March 7th. Oppenheimer lifted their price objective on shares of Xeris Biopharma from $6.00 to $7.00 and gave the company an "outperform" rating in a research note on Friday, May 9th. Craig Hallum lifted their price objective on shares of Xeris Biopharma from $5.00 to $6.50 and gave the company a "buy" rating in a research note on Friday, March 7th. Leerink Partners raised their price target on shares of Xeris Biopharma from $5.00 to $6.00 and gave the stock an "outperform" rating in a research report on Friday, March 7th. Finally, Jefferies Financial Group reissued a "buy" rating and set a $6.00 price target (up previously from $4.00) on shares of Xeris Biopharma in a research report on Wednesday, January 29th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $6.25.

Xeris Biopharma Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.